Brazilian HIV Clinical Forum – presentations

  Tuesday 12 September 2017
  Session 1: Basic Characteristics of Integrase Inhibitors
 
Resistance Characteristics of HIV Integrase Inhibitors
Dr. C. Boucher , Erasmus Medical Center , The Netherlands
 
Is Baseline Resistance Testing Needed?
Dr. R. Díaz , Federal University of São Paulo , São Paulo
  Session 2: Brazilian Infectious Diseases Society
 
Brazilian Guidelines for Antiretroviral Therapy
Dr. J.V. Madruga , Secretariat of Health , São Paulo
 
Clinical Case Discussion 1
Dr. T.R. Constant Vergara , Clínica Geral , Rio de Janeiro
 
Clinical Case Discussion 2
Dr. E.P. Nunes , Evandro Chagas Clinical Research Institute (IPEC)– FIOCRUZ , Rio de Janeiro
 
Clinical Case Discussion 3
Dr. N. Rachid de Lacerda , Conselho Regional de Medicina do Estado do Rio de Janeiro (CREMERJ) , Rio de Janeiro
  Session 3: Integrase Inhibitors in Special Populations
 
The Role of HIV Integrase Inhibitors in PrEP & PEP
Dr. R. Ellion , Whitman-Walker Health , Washington DC
 
HIV Integrase Inhibitors in an Aging Population (Polypharmacy - Comorbidities)
Dr. M.C.Rachid de Lacerda , Conselho Regional de Medicina do Estado do Rio de Janeiro (CREMERJ) , Rio de Janeiro
 
Clinical Case on Integrase Inhibitors Use in TB-Infected Patients
Dr. L. Grinsztejn , Evandro Chagas Clinical Research Institute (IPEC)– FIOCRUZ , Rio de Janeiro